Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The ALPHA phase 1 study: pulmonary ArteriaL hypertension treated with CardiosPHere-Derived allogeneic stem cells

EBioMedicine(2023)10.1016/j.ebiom.2023.104900Source: DataRank Database

The ALPHA phase 1 study: pulmonary ArteriaL hypertension treated with CardiosPHere-Derived allogeneic stem cells is a research paper published in EBioMedicine (2023). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.96)OA: goldTopics (34)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

Shelley Shapiro,Ronald J. Oudiz ORCID,Mamoo Nakamura,D. Geft,Yuri Matusov ORCID

Live enrichment

PubMed:38092579 PMC:PMC10879003 OpenAlex:https://openalex.org/W4389606862

Clinical and Translational Science Institute, University of California, Los Angeles

Grant: UL1TR001881

California Institute for Regenerative Medicine

Grant: CLIN2-09444

National Institutes of Health

Grant: 3UL1TR001881-01S2

UCLA Clinical Translational Science Institute

National Center for Advancing Translational Sciences

FWCI

1.96

Citation Percentile

0.9%

Influential Citations

Citation Trend

2025

2026

goldLicense: CC BY NC ND

journalhttp://www.thelancet.com/article/S2352396423004668/pdf

GOLDhttp://www.thelancet.com/article/S2352396423004668/pdf

publisherhttp://www.thelancet.com/article/S2352396423004668/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2352396423004668?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2352396423004668?httpAccept=text/plain

Fields of Study

Pulmonary Hypertension Research and TreatmentsMesenchymal stem cell researchTransplantation: Methods and OutcomesMedicine03 medical and health sciences0302 clinical medicineHumansPulmonary Arterial HypertensionHeartStroke VolumeHematopoietic Stem Cell Transplantation

MeSH Terms

Pulmonary Arterial HypertensionHeartHumansStroke VolumeHematopoietic Stem Cell Transplantation

Keywords

MedicineStem cellAlpha (finance)Internal medicineCardiologySurgeryBiologyCell biologyRight VentriclePulmonary Arterial HypertensionRegenerative MedicineProgenitor Cell TherapyShort- And Long-term SafetyHematopoietic Stem Cell TransplantationHumansHeartStroke VolumeArticles

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

The ALPHA phase 1 study: pulmonary ArteriaL hypertension treated with CardiosPHere-Derived allogeneic stem cells

FAIR Checklist

Authors (15)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)